May 8th 2024
During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Comparison of BTK Inhibitors Shows Promising Results for Zanubrutinib Over Ibrutinib in CLL/SLL
February 14th 2023An interim analysis of the phase 3 ALPINE study showed stronger results for patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma on the next generation BTK inhibitor zanubrutinib than standard of care ibrutinib.
Read More
Ibrutinib/Venetoclax Prompts Superior uMRD Data in Elderly or Unfit Patients With CLL
January 25th 2023In an interview with Targeted Oncology, Carolyn Owen, MD, discussed findings from the GLOW study of elderly/unfit patients with chronic lymphocytic leukemia that were presented at SOHO 2022.
Read More
ALPINE Trial of Zanubrutinb Improves PFS vs Ibrutinib in CLL and SLL
January 16th 2023In an interview with Targeted Oncology, Jennifer R. Brown, MD, PhD, discussed the findings from the ALPINE study and the effectiveness of zanubrutinib when used for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Read More
Zanubrutinib Stands Up to Ibrutinib in Patients With CLL/SLL
December 13th 2022Phase 3 ALPINE study study results shows that zanubrutinib produced superior progression-free survival results and objective response rate compared with ibrutinib in chronic lymphoma leukemia and small lymphocytic lymphoma.
Read More
Acalabrutinib Appears to Have Quicker Time to Next Therapy Than Ibrutinib in Patients With CLL
December 12th 2022Patients with chronic lymphocytic leukemia on frontline acalabrutinib were more likely to switch to another therapy or intensify their treatment earlier on, compared to those on ibrutinib, according to real-world study data.
Read More
Greater Understanding of CLL Pathophysiology Spurs Small Molecules Development
October 25th 2022William Wierda, MD, PhD, explored the emergence of small molecule-inhibitor targeted therapies during the “Workup of CLL in the Era of Small Molecules,” presentation at the 10th Annual Meeting of the Society of Hematologic Oncology.
Read More
First Patient With B-NHL or CLL Treated With MB-106 in Phase 1/2 Study
October 10th 2022The phase 1/2 clinical trial of MB-106 is demonstrating high efficacy, durable responses, and a favorable safety profile as the first patient treated did not experience cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome
Read More
Should Small Molecules Be Sequenced or Administered in Combination Regimens in CLL?
September 30th 2022During a debate a the SOHO 2022 Annual Meeting, Jennifer R Brown, MD, PhD presented in favor of combining small molecules in CLL. Making the argument for sequencing small molecules in CLL was Anthony Mato, MD.
Read More